118 related articles for article (PubMed ID: 36373323)
1. A Pilot Study of Near-Infrared Light Treatment for Alzheimer's Disease.
Chen L; Xue J; Zhao Q; Liang X; Zheng L; Fan Z; Souare ISJ; Suo Y; Wei X; Ding D; Mao Y
J Alzheimers Dis; 2023; 91(1):191-201. PubMed ID: 36373323
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
3. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
[TBL] [Abstract][Full Text] [Related]
6. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
8. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
10. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
[TBL] [Abstract][Full Text] [Related]
11. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
Aronson S; Van Baelen B; Kavanagh S; Schwalen S
Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
[TBL] [Abstract][Full Text] [Related]
12. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
13. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
14. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
15. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
17. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
18. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
19. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
20. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]